{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:19:21Z","timestamp":1787314761041,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100024838","name":"Samsung Medical Center, Sungkyunkwan University","doi-asserted-by":"publisher","award":["SMC 2023-02-073"],"award-info":[{"award-number":["SMC 2023-02-073"]}],"id":[{"id":"10.13039\/501100024838","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.modpat.2024.100490","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T17:36:30Z","timestamp":1712424990000},"page":"100490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non\u2013Small Cell Lung Cancer: Implications for Precision Medicine"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1820-5923","authenticated-orcid":false,"given":"Yurimi","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7784-5971","authenticated-orcid":false,"given":"Boram","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5788-5140","authenticated-orcid":false,"given":"Yoon-La","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joungho","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.modpat.2024.100490_bib1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.lungcan.2014.12.018","article-title":"Targeting HER2 in the treatment of non-small cell lung cancer","volume":"87","author":"Mar","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.modpat.2024.100490_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2022.1610360","article-title":"Molecular landscape of ERBB2 alterations in 14,956 solid tumors","volume":"28","author":"Wang","year":"2022","journal-title":"Pathol Oncol Res"},{"issue":"12","key":"10.1016\/j.modpat.2024.100490_bib3","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/modpathol.2012.125","article-title":"Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung","volume":"25","author":"Grob","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2024.100490_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103997","article-title":"A\u00a0review of HER2 overexpression and somatic mutations in cancers","volume":"186","author":"Galogre","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100490_bib5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4143\/crt.2019.186","article-title":"Clinical characteristics and outcomes of non-small cell lung cancer patients with HER2 alterations in Korea","volume":"52","author":"Lee","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.modpat.2024.100490_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.lungcan.2014.06.007","article-title":"HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations","volume":"85","author":"Yoshizawa","year":"2014","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.modpat.2024.100490_bib7","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1097\/JTO.0000000000000379","article-title":"NSCLC and HER2: between lights and shadows","volume":"9","author":"Ricciardi","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"issue":"16","key":"10.1016\/j.modpat.2024.100490_bib8","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazi\u00e8res","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.modpat.2024.100490_bib9","article-title":"HER2-altered non-small cell lung cancer: biology, clinicopathologic features, and emerging therapies","volume":"12","author":"Yu","year":"2022","journal-title":"Front Oncol"},{"issue":"21","key":"10.1016\/j.modpat.2024.100490_bib10","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1002\/cncr.30869","article-title":"HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium","volume":"123","author":"Pillai","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.modpat.2024.100490_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100395","article-title":"Consensus for HER2 alterations testing in non-small-cell lung cancer","volume":"7","author":"Ren","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.modpat.2024.100490_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/cas.12845","article-title":"Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations","volume":"107","author":"Suzawa","year":"2016","journal-title":"Cancer Sci"},{"issue":"18","key":"10.1016\/j.modpat.2024.100490_bib13","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.modpat.2024.100490_bib14","article-title":"The frequency and clinical impact of HER2 alterations in lung adenocarcinoma","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.modpat.2024.100490_bib15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers","volume":"11","author":"Li","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2024.100490_bib16","doi-asserted-by":"crossref","first-page":"488","DOI":"10.4143\/crt.2022.359","article-title":"Real world characteristics and clinical outcomes of HER2-mutant non-small cell lung cancer patients detected by next-generation sequencing","volume":"55","author":"Ahn","year":"2023","journal-title":"Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.modpat.2024.100490_bib17","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/1759-7714.13419","article-title":"Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer","volume":"11","author":"Wei","year":"2020","journal-title":"Thorac Cancer"},{"issue":"3","key":"10.1016\/j.modpat.2024.100490_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.modpat.2024.100490_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21873\/cgp.20307","article-title":"High frequency of juxtamembrane domain ERBB2 mutation in gastric cancer","volume":"19","author":"Park","year":"2022","journal-title":"cancer genomics proteomics"},{"issue":"1","key":"10.1016\/j.modpat.2024.100490_bib20","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41467-017-01470-y","article-title":"Prevalence and detection of low-allele-fraction variants in clinical cancer samples","volume":"8","author":"Shin","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.modpat.2024.100490_bib21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13019-020-01199-8","article-title":"Both the presence of a micropapillary component and the micropapillary predominant subtype predict poor prognosis after lung adenocarcinoma resection: a meta-analysis","volume":"15","author":"Wang","year":"2020","journal-title":"J\u00a0Cardiothorac Surg"},{"issue":"9","key":"10.1016\/j.modpat.2024.100490_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100209","article-title":"Efficacy of preoperative biopsy in predicting the newly proposed histologic grade of resected lung adenocarcinoma","volume":"36","author":"Ohtani-Kim","year":"2023","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100490_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23195-9","article-title":"Analysis of non-small cell lung cancer with miliary lung metastasis in patients harboring epidermal growth factor receptor mutations","volume":"12","author":"Chang","year":"2022","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.modpat.2024.100490_bib24","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.3390\/diagnostics11112042","article-title":"Mesonephric-like adenocarcinoma of the uterine corpus: comprehensive immunohistochemical analyses using markers for mesonephric, endometrioid and serous tumors","volume":"11","author":"Kim","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"10.1016\/j.modpat.2024.100490_bib25","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","article-title":"Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas","volume":"35","author":"Ross","year":"2022","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100490_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"10.1016\/j.modpat.2024.100490_bib27","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.modpat.2024.100490_bib28","doi-asserted-by":"crossref","first-page":"206","DOI":"10.17085\/apm.21080","article-title":"Cause of postoperative mortality in patients with end-stage renal disease","volume":"17","author":"Song","year":"2022","journal-title":"Anesth Pain Med (Seoul)"},{"issue":"6","key":"10.1016\/j.modpat.2024.100490_bib29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2024.100490_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100260","article-title":"Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations","volume":"6","author":"Riudavets","year":"2021","journal-title":"ESMO Open"},{"issue":"17","key":"10.1016\/j.modpat.2024.100490_bib31","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.3390\/cancers14174155","article-title":"HER2 in non-small cell lung cancer: a review of emerging therapies","volume":"14","author":"Uy","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.modpat.2024.100490_bib32","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.3390\/cancers14143337","article-title":"Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies","volume":"14","author":"Koulouris","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.modpat.2024.100490_bib33","first-page":"1651","article-title":"Deciphering the impact of HER2 alterations on non-small-cell lung cancer: from biological mechanisms to therapeutic approaches","volume":"12","author":"Bontoux","year":"2022","journal-title":"J\u00a0Pers Med"},{"issue":"8","key":"10.1016\/j.modpat.2024.100490_bib34","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3390\/cancers14081931","article-title":"Acquired mechanisms of resistance to osimertinib-the next challenge","volume":"14","author":"R\u00edos-Hoyo","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.modpat.2024.100490_bib35","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12885-020-06805-5","article-title":"Prognostic value of TP53 concurrent mutations for EGFR-TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis","volume":"20","author":"Qin","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.modpat.2024.100490_bib36","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.lungcan.2018.07.039","article-title":"Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas","volume":"124","author":"Jin","year":"2018","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.modpat.2024.100490_bib37","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/1078-0432.CCR-17-2289","article-title":"The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations-the lung cancer mutation consortium (LCMC2)","volume":"24","author":"Aisner","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.modpat.2024.100490_bib38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jtho.2018.10.150","article-title":"Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced NSCLC","volume":"14","author":"Kim","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"6","key":"10.1016\/j.modpat.2024.100490_bib39","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1097\/MS9.0000000000000719","article-title":"Exploration of HER2 (ERBB2) immunohistochemistry in non-small cell lung cancer: correlation with ERBB2 mutational status: experimental research","volume":"85","author":"Cardillo","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"issue":"6","key":"10.1016\/j.modpat.2024.100490_bib40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jclinpath-2019-206204","article-title":"Pilot evaluation of a HER2 testing in non-small-cell lung cancer","volume":"73","author":"Hotta","year":"2020","journal-title":"J\u00a0Clin Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100490_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5301\/ijbm.5000271","article-title":"Concordance analysis between HER2 immunohistochemistry and in situ hybridization in non-small cell lung cancer","volume":"33","author":"Ko","year":"2018","journal-title":"Int J Biol Markers"},{"issue":"1","key":"10.1016\/j.modpat.2024.100490_bib42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2024.100490_bib43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/MCP.0000000000000070","article-title":"High-grade lung adenocarcinomas with micropapillary and\/or solid patterns: a review","volume":"20","author":"Morales-Oyarvide","year":"2014","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.modpat.2024.100490_bib44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4137\/CMO.S10811","article-title":"Cytoplasmic overexpression of HER2: a key factor in colorectal cancer","volume":"7","author":"Blok","year":"2013","journal-title":"Clin Med Insights Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2024.100490_bib45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4132\/jptm.2021.03.23","article-title":"Molecular biomarker testing for non-small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group","volume":"55","author":"Chang","year":"2021","journal-title":"J\u00a0Pathol Transl Med"},{"issue":"12","key":"10.1016\/j.modpat.2024.100490_bib46","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jtho.2020.08.005","article-title":"The underlying tumor genomics of predominant histologic subtypes in lung adenocarcinoma","volume":"15","author":"Caso","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"14","key":"10.1016\/j.modpat.2024.100490_bib47","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-21-0423","article-title":"Comprehensive molecular and clinicopathologic analysis of 200 pulmonary invasive mucinous adenocarcinomas identifies distinct characteristics of molecular subtypes","volume":"27","author":"Chang","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089339522400070X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089339522400070X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:59:18Z","timestamp":1762315158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089339522400070X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S089339522400070X"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2024.100490","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non\u2013Small Cell Lung Cancer: Implications for Precision Medicine","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2024.100490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100490"}}